Atherosclerosis

20 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Arterial Occlusive Diseases, Arteriosclerosis, Cardiovascular Diseases

Narrower: Peripheral Arterial Disease 2

Treatments and conditions

Atherosclerosis
Treatment and conditionWhere it standsTrials
Calf Plantar flexion + Dietary nitrate for peripheral arterial diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Canakinumab for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clazakizumab for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for atherosclerosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg + Usual Care Group for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Left main stenting with intravascular lithotripsy for atherosclerosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lepodisiran for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lepodisiran Sodium for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Maridebart Cafraglutide for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Muvalaplin for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Polycap for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for peripheral arterial diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selnoflast for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tertinat for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VERVE-102 for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ziltivekimab for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.